Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anne M Connolly

Showing results (81-90 of 118) with videos related to

Pageof 12
Sort By:
Pediatrics|August 27, 2020
Gene Therapy for Spinal Muscular Atrophy: Safety and Early OutcomesMegan A Waldrop, Cassandra Karingada, Mike A Storey, et al.
Journal of Neuromuscular Diseases|November 19, 2023
Findings from the Longitudinal CINRG Becker Natural History StudyPaula R Clemens, Heather Gordish-Dressman, Gabriela Niizawa, et al.
Journal of Neuromuscular Diseases|March 13, 2023
Intrathecal Onasemnogene Abeparvovec for Sitting, Nonambulatory Patients with Spinal Muscular Atrophy: Phase I Ascending-Dose Study (STRONG)Richard S Finkel, Basil T Darras, Jerry R Mendell, et al.
Plos One|October 19, 2020
Medical management of muscle weakness in Duchenne muscular dystrophySarah R Rivera, Sumit K Jhamb, Hoda Z Abdel-Hamid, et al.
Journal of Neuromuscular Diseases|November 19, 2023
Moving Beyond the 2018 Minimum International Care Considerations for Osteoporosis Management in Duchenne Muscular Dystrophy (DMD): Meeting Report from the 3rd International Muscle-Bone Interactions Meeting 7th and 14th November 2022Kim Phung, Nicola Crabtree, Anne M Connolly, et al.
Neuromuscular Disorders : NMD|December 24, 2023
Continued safety and long-term effectiveness of onasemnogene abeparvovec in OhioMegan A Waldrop, Shannon Chagat, Michael Storey, et al.
Muscle & Nerve|February 2, 2019
Twice-weekly glucocorticosteroids in infants and young boys with Duchenne muscular dystrophyAnne M Connolly, Craig M Zaidman, Paul T Golumbek, et al.
Medicine|July 3, 2019
Long-term treatment with eteplirsen in nonambulatory patients with Duchenne muscular dystrophyLindsay N Alfano, Jay S Charleston, Anne M Connolly, et al.
The New England Journal of Medicine|November 2, 2017
Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular AtrophyRichard S Finkel, Eugenio Mercuri, Basil T Darras, et al.
Neurology|March 16, 2018
A multinational study on motor function in early-onset FSHDJean K Mah, Jia Feng, Marni B Jacobs, et al.
Pageof 12

Showing results (81-90 of 118) with videos related to

Sort By:
Pageof 12
Pediatrics|August 27, 2020
Gene Therapy for Spinal Muscular Atrophy: Safety and Early OutcomesMegan A Waldrop, Cassandra Karingada, Mike A Storey, et al.
Journal of Neuromuscular Diseases|November 19, 2023
Findings from the Longitudinal CINRG Becker Natural History StudyPaula R Clemens, Heather Gordish-Dressman, Gabriela Niizawa, et al.
Journal of Neuromuscular Diseases|March 13, 2023
Intrathecal Onasemnogene Abeparvovec for Sitting, Nonambulatory Patients with Spinal Muscular Atrophy: Phase I Ascending-Dose Study (STRONG)Richard S Finkel, Basil T Darras, Jerry R Mendell, et al.
Plos One|October 19, 2020
Medical management of muscle weakness in Duchenne muscular dystrophySarah R Rivera, Sumit K Jhamb, Hoda Z Abdel-Hamid, et al.
Journal of Neuromuscular Diseases|November 19, 2023
Moving Beyond the 2018 Minimum International Care Considerations for Osteoporosis Management in Duchenne Muscular Dystrophy (DMD): Meeting Report from the 3rd International Muscle-Bone Interactions Meeting 7th and 14th November 2022Kim Phung, Nicola Crabtree, Anne M Connolly, et al.
Neuromuscular Disorders : NMD|December 24, 2023
Continued safety and long-term effectiveness of onasemnogene abeparvovec in OhioMegan A Waldrop, Shannon Chagat, Michael Storey, et al.
Muscle & Nerve|February 2, 2019
Twice-weekly glucocorticosteroids in infants and young boys with Duchenne muscular dystrophyAnne M Connolly, Craig M Zaidman, Paul T Golumbek, et al.
Medicine|July 3, 2019
Long-term treatment with eteplirsen in nonambulatory patients with Duchenne muscular dystrophyLindsay N Alfano, Jay S Charleston, Anne M Connolly, et al.
The New England Journal of Medicine|November 2, 2017
Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular AtrophyRichard S Finkel, Eugenio Mercuri, Basil T Darras, et al.
Neurology|March 16, 2018
A multinational study on motor function in early-onset FSHDJean K Mah, Jia Feng, Marni B Jacobs, et al.
Pageof 12